Form 8-K NRX Pharmaceuticals, For: Jul 21

false 0001719406 0001719406 2026-07-21 2026-07-21

 

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT 

PURSUANT TO SECTION 13 OR 15(d) OF THE 

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported) July 21, 2026

 

NRX PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

(484) 254-6134

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

In April 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced the incorporation of NRx Defense Systems, Inc. (“NRXD”), a Florida-based research and development subsidiary charged with the development of neuroplastic treatments that combine D-cycloserine with Transcranial Magnetic Stimulation (“TMS”) under robotic-enabled neuro-navigation, using already developed technology. The Company anticipated NRXD participating in future government and non-governmental research and development, based on phase I and II research conducted by the Company’s Chief Medical Innovation Officer.

 

On July 21, 2026, NRXD received a letter from the Defense Advanced Research Projects Agency (“DARPA”), Defense Sciences Office (DSO), notifying the Company that its proposal to conduct a clinical trial, entitled Synaptic Plasticity Augmented Rapid Circuit Stimulation (SPARC-TMS) had been selected by DARPA for negotiation of a potential award.

 

The protocol for the SPARC-TMS trial was approved as a phase 2/3 trial by the US Food and Drug Administration (FDA) and is posted on www.clinicaltrials.gov (NCT07227103). The trial aims to demonstrate the potential efficacy of robotic-enabled Transcranial Magnetic Stimulation combined with NRX-101 (combined D-cycloserine/lurasidone) in achieving remission from depression. NRX-101 which is patented by the Company was previously awarded Breakthrough Therapy Designation by the FDA. The study is planned to be conducted at Harvard Mclean hospital, at clinics operated by HOPE Therapeutics, and at designated military treatment facilities including the Walter Reed National Military Medical Center.

 

The selection of the Company’s proposal for contract negotiation does not constitute a notice of award, a commitment by DARPA to make an award or an authorization for the Company to incur costs. Any potential award remains subject to the successful negotiation of definitive terms between DARPA/DSO and NRXD.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.